与甲列丁的使用相关的不良药物事件:使用FAERS数据库从2014年到2024年的真实世界药监测研究
Jinhao He1, Xuehu Luo1, Jie Liu1
1Department of Pharmacy, The Third Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital of Chengdu, Chengdu, Sichuan, China.
Expert opinion on drug safety
|December 18, 2024
概括
这项研究确定了100多个对甲列列的不良药物事件信号,其中57个新信号不在药物标签上. 胃肠道问题与住院有关,为更安全的临床使用提供了信息.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 临床药理学 临床药理学
背景情况:
- 药物不良事件 (ADEs) 是患者护理中的一个重要问题.
- 梅特利普丁用于特定的代谢障碍,需要对安全性进行监测.
- 了解ADE信号对于优化治疗策略至关重要.
研究的目的:
- 分析与metreleptin相关的不良药物事件 (ADE) 信号.
- 为安全的临床使用metreleptin提供见解.
- 为了确定与美特利普丁治疗相关的住院治疗的潜在风险因素.
主要方法:
- 从2014年1月到2024年3月使用了FDA不良事件报告系统 (FAERS) 数据库.
- 使用多种统计方法评估信号强度:ROR,MHRA,BCPNN和MGPS.
- 分析了Weibull形状参数 (WSP) 的时间到发病 (TTO) 并通过后勤回归识别了住院风险因素.
主要成果:
- 识别了4000个ADE报告,其中有1025个重大事件,主要发生在女性身上,并由医疗保健专业人员报告.
- 在所有方法中确认了101个首选术语 (PT) 信号,其中包括57个以前未在药物标签上列出的PT.
- 观察到的TTO中位数为547天;胃肠道疾病和调查被确定为住院风险因素.
结论:
- 这项研究突出了对甲列相关的ADEs的发病时间的关键见解.
- 调查结果强调了持续监测潜在副作用的重要性.
- 结果告诉metreleptin更安全的临床应用,改善患者的治疗结果.
相关概念视频
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
245
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
245
Antiepileptic Drugs: Potassium Channel Activators
143
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
143
Renal Failure: Dose Adjustments
63
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
63
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
80
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
80
Local Anesthetics: Adverse Effects
386
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
386


